Press Release

Göteborg July 16, 2021

IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam

IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET.

The presentation will be held by IRLAB's CEO Nicholas Waters and CFO Viktor Siewertz in English and will conclude with a Q&A session. Questions can be asked live or in written form through the webcast.

Date and time
Friday July 16, 2021, at 10:00 CET.

Webcast link
https://bit.ly/IRLAB-License-Webinar

Phone number
+46 8 505 218 97 with code 545658623#

The presentation will be recorded and may be published afterwards.

cokinetics (PK) of pirepemat administered as oral single ascending doses (10, 35, 75, 175, 350 mg) and multiple ascending
doses (100 and 250 mg 3 times daily) for 7 days to healthy male volunteers. Twenty and 24 subjects were randomly
assigned in the single ascending dose and multiple ascending doses parts of the study, respectively. Pirepemat was gener-
ally well tolerated, although an increased frequency of adverse events of mild intensity within nervous system disorders
(headache and dizziness) was seen after administration of 350 mg as a single dose and after multiple doses of 100 and
250 mg. PK of pirepemat showed a linear relationship over the dose range studied and exhibited dose proportionality
after multiple-dose administration. Accumulation after 7 days of multiple dosing was minor. Absorption was rapid, with a

median time to maximum concentration of 2.0 hours on day 1 and day 7 (100 and 250 mg) and a mean terminal half-life
between 3.7 and 5.2 hours. Food intake had no (obvious) impact on PK. The results support 3-times-daily dosing and
further clinical development.
This rst-in-human, randomized, double-blind,placebo-controlled phase 1 study evaluated safety, tolerability,and pharma-
cokinetics (PK) of pirepemat administered as oral single ascending doses (10, 35, 75, 175, 350 mg) and multiple ascending
doses (100 and 250 mg 3 times daily) for 7 days to healthy male volunteers. Twenty and 24 subjects were randomly
assigned in the single ascending dose and multiple ascending doses parts of the study, respectively. Pirepemat was gener-
ally well tolerated, although an increased frequency of adverse events of mild intensity within nervous system disorders
(headache and dizziness) was seen after administration of 350 mg as a single dose and after multiple doses of 100 and
250 mg. PK of pirepemat showed a linear relationship over the dose range studied and exhibited dose proportionality
after multiple-dose administration. Accumulation after 7 days of multiple dosing was minor. Absorption was rapid, with a
median time to maximum concentration of 2.0 hours on day 1 and day 7 (100 and 250 mg) and a mean terminal half-life
between 3.7 and 5.2 hours. Food intake had no (obvious) impact on PK. The results support 3-times-daily dosing and
further clinical development.

For more information

Nicholas Waters, CEO
Phone: +46 730 75 77 01
E-mail: nicholas.waters@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

Press Release

Göteborg July 16, 2021

About IRLAB

IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson's disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PDP) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS)-related disorders where large and growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. The project portfolio comprises a combination of the fully-funded mesdopetam program, run in collaboration with global partner Ipsen, as well as innovative in-house programs from preclinical to Phase IIb. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.

Attachments

IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam